Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents, Phytogenic | 11 | 2018 | 621 | 1.770 |
Why?
|
| Paclitaxel | 12 | 2018 | 1732 | 1.630 |
Why?
|
| Nanoparticles | 11 | 2018 | 1959 | 0.950 |
Why?
|
| Drug Carriers | 6 | 2018 | 706 | 0.760 |
Why?
|
| Polymers | 5 | 2018 | 1617 | 0.570 |
Why?
|
| Mesothelioma | 5 | 2017 | 807 | 0.550 |
Why?
|
| Peritoneal Neoplasms | 3 | 2017 | 711 | 0.480 |
Why?
|
| Drug Delivery Systems | 5 | 2016 | 2226 | 0.470 |
Why?
|
| Pulmonary Ventilation | 2 | 2007 | 372 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2018 | 9280 | 0.400 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 2016 | 0.370 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 111 | 0.350 |
Why?
|
| Bronchi | 1 | 2014 | 845 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 5315 | 0.320 |
Why?
|
| Chondrosarcoma | 1 | 2011 | 296 | 0.320 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2007 | 517 | 0.310 |
Why?
|
| Ventilators, Mechanical | 2 | 2007 | 288 | 0.300 |
Why?
|
| Lung Neoplasms | 7 | 2017 | 13380 | 0.290 |
Why?
|
| Vasoconstriction | 2 | 2007 | 592 | 0.250 |
Why?
|
| Mice, Nude | 5 | 2017 | 3615 | 0.200 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 4915 | 0.200 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 908 | 0.190 |
Why?
|
| Respiratory Insufficiency | 2 | 2007 | 1230 | 0.190 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3466 | 0.190 |
Why?
|
| Pulmonary Artery | 2 | 2007 | 1927 | 0.170 |
Why?
|
| Lung | 4 | 2007 | 10000 | 0.150 |
Why?
|
| Cell Line, Tumor | 10 | 2018 | 16981 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 4 | 2017 | 6132 | 0.140 |
Why?
|
| Hypertension, Pulmonary | 2 | 2005 | 1578 | 0.140 |
Why?
|
| Nanofibers | 1 | 2015 | 66 | 0.130 |
Why?
|
| Bronchoconstriction | 2 | 2007 | 142 | 0.130 |
Why?
|
| Pulmonary Circulation | 3 | 2007 | 737 | 0.120 |
Why?
|
| Peritoneum | 1 | 2016 | 225 | 0.120 |
Why?
|
| Pinocytosis | 1 | 2015 | 62 | 0.120 |
Why?
|
| Mice | 16 | 2018 | 81525 | 0.120 |
Why?
|
| Polyglactin 910 | 1 | 2014 | 55 | 0.120 |
Why?
|
| Animals | 21 | 2018 | 168459 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 18252 | 0.120 |
Why?
|
| Polyesters | 2 | 2018 | 373 | 0.110 |
Why?
|
| Vascular Resistance | 2 | 2007 | 930 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2007 | 705 | 0.110 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2010 | 108 | 0.100 |
Why?
|
| Microscopy, Confocal | 3 | 2015 | 1971 | 0.100 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 4 | 2016 | 398 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 6 | 2015 | 22169 | 0.100 |
Why?
|
| Vasodilation | 2 | 2007 | 962 | 0.100 |
Why?
|
| Carcinoma | 2 | 2012 | 2330 | 0.090 |
Why?
|
| Cisplatin | 1 | 2015 | 1651 | 0.080 |
Why?
|
| Biocompatible Materials | 2 | 2015 | 1685 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 21012 | 0.080 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2007 | 214 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 4876 | 0.070 |
Why?
|
| Albumins | 1 | 2010 | 575 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 3602 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2018 | 2321 | 0.070 |
Why?
|
| Camptothecin | 1 | 2010 | 591 | 0.070 |
Why?
|
| Myocardial Reperfusion | 1 | 2007 | 338 | 0.070 |
Why?
|
| Benzoates | 1 | 2007 | 212 | 0.070 |
Why?
|
| Rhodamines | 2 | 2017 | 178 | 0.060 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 128 | 0.060 |
Why?
|
| Morpholines | 1 | 2007 | 581 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 857 | 0.050 |
Why?
|
| Lysine | 1 | 2007 | 993 | 0.050 |
Why?
|
| Cell Survival | 4 | 2017 | 5791 | 0.050 |
Why?
|
| Collagen | 1 | 2010 | 2638 | 0.050 |
Why?
|
| Female | 11 | 2017 | 392644 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 13639 | 0.040 |
Why?
|
| Nitric Oxide | 2 | 2007 | 2135 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5368 | 0.040 |
Why?
|
| Kinetics | 2 | 2018 | 6374 | 0.040 |
Why?
|
| Wound Healing | 1 | 2009 | 2805 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2010 | 945 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 2496 | 0.040 |
Why?
|
| Fluorescent Dyes | 2 | 2017 | 1903 | 0.040 |
Why?
|
| Succinic Acid | 1 | 2018 | 86 | 0.040 |
Why?
|
| Ethanol | 2 | 2015 | 1324 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12725 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2007 | 2009 | 0.030 |
Why?
|
| Quality of Life | 1 | 2018 | 13367 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3712 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2017 | 413 | 0.030 |
Why?
|
| Surface-Active Agents | 1 | 2017 | 150 | 0.030 |
Why?
|
| Humans | 12 | 2018 | 761504 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8529 | 0.030 |
Why?
|
| Pyridines | 1 | 2007 | 2875 | 0.030 |
Why?
|
| Cyclic GMP | 2 | 2007 | 395 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 3028 | 0.030 |
Why?
|
| Excipients | 1 | 2015 | 98 | 0.030 |
Why?
|
| Echocardiography | 1 | 2007 | 4989 | 0.030 |
Why?
|
| Carboxylic Acids | 1 | 2015 | 90 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2015 | 84 | 0.030 |
Why?
|
| Myocardium | 1 | 2007 | 4726 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 274 | 0.030 |
Why?
|
| Sheep | 2 | 2007 | 1440 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2014 | 94 | 0.030 |
Why?
|
| Glycerol | 1 | 2015 | 274 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 10766 | 0.030 |
Why?
|
| Administration, Inhalation | 2 | 2007 | 1157 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2014 | 330 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 330 | 0.030 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2012 | 57 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 1229 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 2265 | 0.030 |
Why?
|
| Neoplasms | 2 | 2018 | 22170 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2015 | 290 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2014 | 338 | 0.020 |
Why?
|
| Surgical Mesh | 1 | 2014 | 311 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 575 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 39967 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2010 | 246 | 0.020 |
Why?
|
| Purinones | 1 | 2007 | 13 | 0.020 |
Why?
|
| Powders | 1 | 2007 | 80 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 2007 | 94 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 1161 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 1189 | 0.020 |
Why?
|
| Guanylate Cyclase | 1 | 2007 | 205 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 718 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 1 | 1 | 2005 | 6 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 962 | 0.020 |
Why?
|
| Vinca Alkaloids | 1 | 2005 | 36 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2007 | 296 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2007 | 629 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1379 | 0.020 |
Why?
|
| Aerosols | 1 | 2007 | 635 | 0.010 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 201 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2014 | 1868 | 0.010 |
Why?
|
| Leukotrienes | 1 | 2005 | 231 | 0.010 |
Why?
|
| Particle Size | 1 | 2007 | 1648 | 0.010 |
Why?
|
| Tissue Scaffolds | 1 | 2010 | 934 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8465 | 0.010 |
Why?
|
| Male | 2 | 2014 | 360804 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10209 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 1755 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2007 | 2048 | 0.010 |
Why?
|
| Mice, Knockout | 2 | 2007 | 14414 | 0.010 |
Why?
|
| Rats | 1 | 2017 | 23742 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2005 | 2678 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2005 | 1113 | 0.010 |
Why?
|
| Apoptosis | 1 | 2015 | 9486 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 2112 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2005 | 4159 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7237 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10445 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 64680 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 74206 | 0.010 |
Why?
|
Concepts
(145)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_